Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome

British Journal of Cancer

Volumn 107, Issue 4, 2012, Pages 675-683

  Zhang, Y Q ^a   Pilyugin, M ^a   Kuester, D ^b   Leoni, V P ^c   Li, L ^a,e   Casula, G ^c   Zorcolo, L ^c   Schneider Stock, R ^b,d   Atzori, L ^c   Irminger Finger, I ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e BEIJING HOSPITAL   (China)

Author keywords

BARD1 isoforms; BRCA1; colorectal cancer; differential splicing; predictive biomarker

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; EPITOPE; MESSENGER RNA;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER TISSUE; CARBOXY TERMINAL SEQUENCE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA METHYLATION; EPITOPE MAPPING; ESTROGENS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION;

EID: 84864882190     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.297     Document Type: Article

References (43)

1. Baer R, Ludwig T (2002) The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 12: 86-91
2. Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, Norris G, Nguyen LB, Jagannathan J, Laquaglia M, Winter C, Diamond M, Hou C, Attiyeh EF, Mosse YP, Pineros V, Dizin E, Zhang Y, Asgharzadeh S, Seeger RC, Capasso M, Pawel BR, Devoto M, Hakonarson H, Rappaport EF, Irminger-Finger I, Maris JM (2012) Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res 72(8): 2068-2078
3. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94: 1365-1372
4. Dizin E, Irminger-Finger I (2010) Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1. Int J Biochem Cell Biol 42: 693-700
5. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265-271
6. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barrière C, Bignon YJ, Ramus S, Benitez J, Caldes T, Akiyama Y, Yuasa Y, Launonen V, Canal MJ, Rodriguez R, Capella G, Peinado MA, Borg A, Aaltonen LA, Ponder BA, Baylin SB, Herman JG (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10: 3001-3007
7. Fabbro M, Rodriguez JA, Baer R, Henderson BR (2002) BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J Biol Chem 277: 21315-21324
8. Figueredo A, Coombes ME, Mukherjee S (2008) Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev CD005390
9. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692-695
10. Garcia-Patiño E, Gomendio B, Lleonart M, Silva JM, Garcia JM, Provencio M, Cubedo R, España P, Ramón y Cajal S, Bonilla F (1998) Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer. Cancer Genet Cytogenet 104: 119-123
11. Gautier F, Irminger-Finger I, Grégoire M, Meflah K, Harb J (2000) Identification of an apoptotic cleavage product of BARD1 as an autoantigen: a potential factor in the antitumoral response mediated by apoptotic bodies. Cancer Res 60: 6895-6900
12. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T (2001) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276: 14537-14540
13. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826
14. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E (2007) Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev CD001216
15. Hogan AM, Collins D, Baird AW, Winter DC (2009) Estrogen and its role in gastrointestinal health and disease. Int J Colorectal Dis 24: 1367-1375
16. Irminger-Finger I, Jefford CE (2006) Is there more to BARD1 than BRCA1? Nat Rev Cancer 6: 382-391
17. Irminger-Finger I, Soriano JV, Vaudan G, Montesano R, Sappino AP (1998) In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells. J Cell Biol 143: 1329-1339
18. Joukov V, Chen J, Fox EA, Green JB, Livingston DM (2001) Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development. Proc Natl Acad Sci USA 98: 12078-12083
19. Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D, Peretz T (2007) Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 44: 467-471
20. Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, Rapaport H, Nafa K, Ellis NA, Offit K (2004) Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 96: 68-70
21. Li L, Ryser S, Dizin E, Pils D, Krainer M, Jefford CE, Bertoni F, Zeillinger R, Irminger-Finger I (2007) Oncogenic BARD1 isoforms expressed in gynecological cancers. Cancer Res 67: 11876-11885
22. Lin KM, Ternent CA, Adams DR, Thorson AG, Blatchford GJ, Christensen MA, Watson P, Lynch HT (1999) Colorectal cancer in hereditary breast cancer kindreds. Dis Colon Rectum 42: 1041-1045
23. Lynch HT, Lemon SJ, Karr B, Franklin B, Lynch JF, Watson P, Tinley S, Lerman C, Carter C (1997) Etiology, natural history, management and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes): genetic counseling implications. Cancer Epidemiol Biomarkers Prev 6: 987-991
24. Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361: 2449-2460
25. Meza JE, Brzovic PS, King M-C, Klevit RE (1999) Mapping the functional domains of BRCA1. J Biol Chem 274: 5659-5665
26. Mohamad HB, Apffelstaedt JP (2008) Counseling for male BRCA mutation carriers: a review. Breast 17: 441-450
27. Morris JR, Solomon E (2004) BRCA1:BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum Mol Genet 13: 807-817
28. Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96: 15-21
29. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, Deng C, Sen S, Lee SW, Ouchi T (2004) BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 279: 19643-19648
30. Oyake D, Nishikawa H, Koizuka I, Fukuda M, Ohta T (2002) Targeted substrate degradation by an engineered double RING ubiquitin ligase. Biochem Biophys Res Commun 295: 370-375
31. Rudmik LR, Magliocco AM (2005) Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 92: 347-359
32. Russo A, Calò V, Bruno L, Rizzo S, Bazan V, Di Fede G (2009) Hereditary ovarian cancer. Crit Rev Oncol Hematol 69: 28-44
33. Ryser S, Dizin E, Jefford CE, Delaval B, Gagos S, Christodoulidou A, Krause K-H, Birnbaum D, Irminger-Finger I (2009) Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2. Cancer Res 69: 1125-1134
34. Schneider-Stock R, Boltze C, Peters B, Höpfner T, Meyer F, Lippert H, Roessner A (2003) Differences in loss of p16INK4 protein expression by promoter methylation between left-and right-sided primary colorectal carcinomas. Int J Oncol 23: 1009-1013
35. Sporn JC, Hothorn T, Jung BH (2011) BARD1 expression predicts outcome in colon cancer. Clin Cancer Res 17(16): 5451-5462
36. Srebrow A, Kornblihtt AR (2006) The connection between splicing and cancer. J Cell Sci 119: 2635-2641
37. Starita LM, Machida Y, Sankaran S, Elias JE, Griffin K, Schlegel BP, Gygi SP, Parvin JD (2004) BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol 24: 8457-8466
38. Suchy J, Cybulski C, Górski B, Huzarski T, Byrski T, D?ebniak T, Gronwald J, Jakubowska A, Wokołorczyk D, Kurzawski G, Kładny J, Jawień A, Banaszkiewicz Z, Wiśniowski R, Wandzel P, Starzewski J, Lorenc Z, Korobowicz E, Krokowicz P, Horbacka K, Lubiński J, Narod SA (2010) BRCA1 mutations and colorectal cancer in Poland. Fam Cancer 9: 541-544
39. Wang Q, Zhang H, Guerrette S, Chen J, Mazurek A, Wilson T, Slupianek A, Skorski T, Fishel R, Greene MI (2001) Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. Oncogene 20: 4640-4649
40. WHO (February 2009) Cancer. World Health Organization Geneva
41. WHO (February 2009) Cancer. World Health Organization: Geneva Wu J-Y, Vlastos A-T, Pelte M-F, Caligo M-A, Bianco A, Krause K-H, Laurent GJ, Irminger-Finger I (2006) Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. Int J Cancer 118: 1215-1226
42. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang M-CW, Hwang L-Y, Bowcock AM, Baer R (1996) Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14: 430-440
43. Zhang Y-Q, Bianco A, Malkinson AM, Leoni VP, Frau G, Rosa ND, André P-A, Versace R, Boulvain M, Laurent GJ, Atzuri L, Irminger-Finger I (2012) BARD1: an independent predictor of survival in non-small cell lung cancer. International Journal of Cancer 131(1): 83-94